You are here

Home » Content

Anjiotensin dönüştürücü enzim ve I/D polimorfizmi

Angiotensin Converting Enzyme and I/D Polymorphism

Journal Name:

  • Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2005

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
The renin-angiotensin system plays a role in the pathogenesis of cardiovascular diseases and the efficacy of angiotensin converting enzyme (ACE) inhibitors in the treatment of hypertension and heart failure emphasize the prominent role of ACE in the cardiovascular system. This review aims to discuss angiotensin converting enzyme and I/D polymorphism. ACE converts angiotensin I to the potent vasoconstrictor angiotensin II and that degrades bradykinin. ACE gene is located on human chromosome 17 expressing three genotypes within the intron 16 of the related gene structure. These genotypes are classified as I and D alleles which are termed as insertion and deletion, respectively. The D allele has been associated with an increased risk of developing several pathological processes, such as coronary heart disease and ventricular hypertrophy. Several cardiac conditions appear to have a worse prognosis in subjects homozygous for the D allele, whereas the I allele has been associated with enhanced endurance performance in sportsmen.
Bookmark/Search this post with
Abstract (Original Language): 
Renin-anjiotensin sisteminin kardiovasküler hastalıkların patogenezinde rolü bulunmaktadır ve kalp yetmezliği ile hipertansiyon tedavisinde kullanılan anjiotensin dönüştürücü enzim (ADE) inhibitörleri kardiovasküler sistemde ADE'nin önemli rolünü vurgulamaktadır. Bu yazı ile ADE vel/D polimorfizmi bilgileri derlenmiştir. ADE, anjiotensin I'i kuvvetli bir vazokonstriktör olan anjiotensin Il'e dönüştürür ve bradikininin etkinliğini azaltır. ADE geni insan 17.kromozomunda intron 16'da üç genotip olarak eksprese olur. Bu genotipler "insertion" ve "deletion" olarak isimlendirilen IveD alelleridir. D aleli, koroner kalp hastalığı ve ventriküler hipertrofi gibi birçok patolojik durumun gelişme riskinde artışla ilişkilidir. D alelli homozigot kişiler birçok kardiak durumda kötü bir prognoza sahiptir. I aleli ise sporcularda dayanıklılık performanslarında artış ile ilişkilidir.
FULL TEXT (PDF): 
PDF icon d-polimorfizmi.pdf
  • 4
53-57
  • Turkish

REFERENCES

References: 

1. Baudin B. New aspect on angiotensin-converting enzyme: from gene to disease. Clin Chem Lab Med 2002; 40: 256-65.
2. Soubrier F, Hubert C, Testut P, Nadaud S, Alhenc-Gelas F, Corvol P. Molecular biology ofthe angiotensin I converting enzyme, I: biochemistry and structure of the gene.JHypertens 1993; 11: 471-6.
3. Pelc LR, Gross GJ, Warltier DC. Mechanisms of coronary vasodilatation produced by bradykinin. Circulation 1991; 83: 2048-56.
4. Baudin B, Berard M, Carrier JL, Legrand Y, Drouet L. Vascular origin determines angiotensin I-converting expression in endothelial cells. Endothelium 1997; 5:
73-84.
5. Rieder MJ, Taylor SL, Clark AG, Nickerson DA. Sequence variation in the human angiotensin converting enzyme. Nat Genet 1999; 22: 59-62.
6. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin-1-converting enzyme gene accounting for halfthe variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-6.
7. Prasad A, Narayanan S, Waclawiw MA, Epstein N, Quyyumi AA. The insertion/deletion polymorphism ofthe angiotensin-converting enzyme gene determines coronary vascular tone and nitric oxide activity. J Am Coll Cardiol 2000; 36: 1579-86.
8. Villard E, Soubrier F. Molecular biology and genetics ofthe angiotensin I-converting enzyme: potential implications in cardiovascular diseases. Cardiovasc Res 1996; 32: 999-1007.
9. Butler R, Morris AD, Burchell B, Struthers AD. DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. Hypertension 1999; 33: 1164-8.
10. Cambien F, Poirier O, LecerfL, Evans A, Cambou JP, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.
S.D.Ü. Tıp pak.
Derg
. 2005:12(4)/ 53-57
56
Turgut, ADE I /D polimorfizmi
11. Marian AJ, Yu Q, Workman R, Greve G, Roberts R. Angiotensin converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993; 342: 1085-6.
12. Butler R, Morris AD, Struthers AD. Angiotensin-converting enzyme gene polymorphism and cardiovasculardisease. Clin Sci 1997; 93: 391-400.
13. Alvarez R, Reguero JR, Batalla A, Iglesias-Cubero G, Cortina A, Alvarez V, et al. Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res 1998; 40: 375-9.
14. Alvarez R, Terrados N, Ortolano R, Iglesias-Cubero G, Reguero JR, Batalla A, et al. Genetic variation in the rennin-angiotensin system and athletic performance. EurJAppl Physiol 2000; 82: 117-120.
15. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE gene polymorphism in cardiovascular disease: meta-analyses ofsmall and large studies in whites. Arterioscler Thromb Vasc Biol 2000; 20: 484¬92.
16. Akar N, Aras O, Omürlü K, Cin S. Deletion polymorphism at the angiotensin-converting enzyme gene in Turkish patients with coronary artery disease, Scandinavian Journal ofClinical and Laboratory Investigation 1998; 58:491-5.
17. Candy GP, Skudicky D, Mueller U. Association ofleft ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy. Am J Cardiol 1999; 83: 740-4.
18. Raynolds MV, Bristow MR, Bush EW. Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1073-5.
19. Andersson B, Blange I, Sylven. Angiotensin-type 1 receptor gene polymorphism and long-term survival in patients with idiopathic chronic heart failure. Eur J HeartFail 1 1999: 363-9.
20. Barley J, Blackwood A, Carter ND. Angiotensin converting enzyme insertion/deletion polymorphism: association with ethnic origin. J Hypertension 1994; 12: 955-7.
21. Foy CA, Rice GI, Ossey-Gerning N, Mansfield MW, Grant PJ. Angiotensin converting enzyme (ADE) gene polymorphisms in patients characterized by coronary angiography. Hum Genet 1997; 100: 420-5.
22. Bedir A, Arik N, Adam B, Kılınç K, Gümüş T, Güner E. Angiotensin converting enzyme gene polymorphism and activity in Turkish patients with essential hypertension, American Journal ofHypertension 1999; 12: 1038-43.
23. O'Donnell CJ, Lindpainter K, Larson MG, Ordovas JM, Myers RH, Levy D. The ACE deletion insertion polymorphism and hypertension: an association in the Framingham Heart Study (abstract). J Am Coll Cardiol
1997;29 (supplA): 84A.
24. Schmidt S, van Hooft IM, Grobbee DE, Ganten D, Ritz E. Polymorphism ofthe angiotensin I converting enzyme gene is apparently not related to high blood pressure. JHypertens 1993; 11: 345-8.
25. Araz M, Aynacıoglu S, Aktaran S, Alaşehirli B, Okan V. Association between polymorphism ofthe angiotensin I converting enzyme gene and hypertension in Turkish type II diabetic patients, Acta Medica 2001; 44: 29-32.
26. Tiret L, Blanc H, Ruidavets JB, Arveiler D, Luc G, Jeunemaitre X, et al. Gene polymorphisms ofthe renin-angiotensin system in relation to hypertension and parental history ofmyocardial infarction and stroke. JHypertens. 1998; 16: 37-44.
27. Schumann M, Reichel P, Muller-Myhsok B, Dieringer T, Wurm K, Schlaak M, et al. Angiotensin-converting enzyme (ACE) gene polymorphisms and familial occurrence ofsarcoidosis. J Intern Med 2001; 249: 77¬83.
28. Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 1994; 23: 258-68.
29. Morishita R, Gibbons GH, Ellison KE. Evidence for direct local effect ofangiotensin in vascular hypertrophy. In vivo gene transfer ofangiotensin converting enzyme. J Clin Invest 1994; 94: 978-84.
30. Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales MF, et al. Plasma level and gene polymorphism ofangiotensin converting enzyme in relation to myocardial infarction. Circulation 1994; 90: 669-76.
31. Payne MN, Mc Donald F, Murray RG, Barlett WA. Plasma angiotensin-converting enzyme activity and carotid wall thickening (letter). Circulation 1994; 90:
2566.
32. Nomura H, Koni I, Michishita Y, Morise T, Takeda R. Angiotensin-converting enzyme gene polymorphism inhaemodialysis patients. Lancet 1994; 343: 482.
33. Baudin B. Angiotensin I-converting enzyme gene polymorphism and drug response. Clin Chem Lab Med 2000; 38: 853-6.
34. Friedl W, Krempler F, Sandhofer F, Paulweber B. Insertion-deletion polymorphism in the angiotensin converting enzyme gene and blood pressure during ergometry in normal males. Clin Genet 1996; 50: 541-4.
35. Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi AM, Hemingway H, et al. Association of Angiotensin-converting enzyme gene I/D polymorphism with change in left ventricular mass in response to physicaltraining. Circulation 1997; 96: 741-7.
36. Lachurie ML, Azizi M, Guyene TT, Alhenc-Gelas F, Menard J. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating
S.D.Ü. Tıp pak.
Derg
. 2005:12(4)/ 53-57
Turgut, ADE I /D polimorfizmi
57
renin-angiotensin-aldeosterone system or blood pressure innormotensive subjects. Circulation 1995; 91:
2933-42.
37. Rankinen T, Wolfarth B, Simoneau JA, Maier-Lenz D, Rauramaa R, Rivera MA, et al. No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status. J Appl Physiol 2000; 88: 1571-5.
38. Gayagay G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS, et al. Elite endurance athletes and the ADE I allele. The role ofgenesis in athletic performance. HumGenet 1998; 103: 48-50.
39. Montgomery HE, Clarkson P, Barnard M, Bell J, Brynes A, Dollery C, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism and response to physicaltraining. Lancet 1999; 353: 541-5.
40. Williams AG, Rayson MP, Jubb M, World M, Woods DR, Hayward M, et al. The ADE gene and muscle performance. Nature 2000; 403: 614.
41. Montgomery HE, Marshall RM, Hemingway H, Myerson S, Clarkson P, Dollery C, et al. Human gene forphysicalperformance. Nature 1998; 393: 221-2.
42. Taylor RR, Mamotte CDS, Fallon K, Bockxmeer FM. Elite athletes and the gene for angiotensin-converting enzyme.JAppl Physiol 1999; 87: 1035-7.
43. Nazarov IB, Woods DR, Montgomery HE, Shneider OV, Kazakov VI, Tomilin NV, et al. The angiotensin converting enzyme I/D polymorphism in Russian athletes. Eur J Hum Genet 2001; 9: 797-801.
44. Turgut G, Turgut S, Genç O, Atalay A, Atalay EÖ. The Angiotensin Converting Enzyme I/D Polymorphism In Turkish Athletes And Sedentary Controls. ActaMedica2004; 47: 133-6.

Thank you for copying data from http://www.arastirmax.com